CN108794645A - A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α - Google Patents
A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α Download PDFInfo
- Publication number
- CN108794645A CN108794645A CN201810768833.0A CN201810768833A CN108794645A CN 108794645 A CN108794645 A CN 108794645A CN 201810768833 A CN201810768833 A CN 201810768833A CN 108794645 A CN108794645 A CN 108794645A
- Authority
- CN
- China
- Prior art keywords
- ifn
- fusion protein
- leu
- gene
- bov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a kind of fusion proteins and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α; the fusion protein is connected through flexible linker with Bov IFN α by bovine albumin, Bov IFN γ and is formed, through being freeze-dried to obtain recombinant bovine long-acting interferon after fusion protein and freeze drying protectant mixture.The recombinant bovine long-acting interferon is remarkably improved the half-life period of Bov IFN, and the half-life period of more common Bov IFN improves 18 times or more, and has broad-spectrum disease resistance toxic action and can improve the immune response of Niu Zishen.
Description
Technical field
The invention belongs to technical field of biological genetic engineering, and in particular to be interfered by bovine albumin, Bov IFN γ and ox
The fusion protein and preparation method thereof of plain α compositions.
Background technology
Ox is important one of the herding type in China, with intensive and large-scale cultivation continuous development, bovine viral
The incidence of communicable disease improves year by year.Large-scale pasture is popular for a long time at home for the communicable disease of many oxen, because
Disease infects fast, the high sound development that seriously restrict China's ox aquaculture of incidence, the death rate;More seriously some
Poultry suffers from the life and health that brucellosis, tuberculosis of infectious disease such as ox etc. directly threaten the mankind altogether.
By vaccine inoculation and antibiotic mainly is used to the prevention and treatment approach of ox communicable disease at present.Big portion
Antibiotics and traditional oral antiviral medicament is divided to be brought a negative impact to health due to medicament residue problem;And
Traditional vaccine, the high specific due to it and side effect, can not resist virus variation and new virus continuously emerges to pig
The significant damage that aquaculture is brought.Interferon determines its tool with the antiviral activity of its wide spectrum and extensive immunoregulation capability
There are huge clinical application potentiality, can be used for preventing and treating bovine viral bacterial infection disease.
IFN is that the infection induced body of a viroid is generated with broad-spectrum antiviral, antitumor and with immunoregulation effect
Protein, nineteen fifty-seven, Issacs and Lindeman had found first, it is a kind of multi-functional cell factor, with cell receptor knot
After conjunction, it can induce body and generate a variety of specific proteins and enzyme, mainly by inhibiting viral gene transcription and degradation virus
RNA inhibits the growth and breeding of virus and plays antitumor etc. activity.Now it is known that α types IFN in vivo can be selectively
Act on the infection cells such as virus, by inhibit infected cell in virus protein biosynthesis, play wide spectrum and efficiently
Antivirus action.But it is faint without acting on or acting on to normal host cell.IFN-α main physiological activity is with inhibition virus
Duplication, the killing activity for anti parasitic, inhibiting various kinds of cell proliferation, stimulating immunocyte.
γ types IFN is the T cell and the generation of NK cells by activating, and has relatively strong antiviral and immunoloregulation function.Largely
Studies have shown that interferon gamma also plays crucial adjustment effect other than having the function of broad-spectrum antiviral, to immune system, so
IFN-γ is also known as immunological regulation interferon.Although various types of interferon can mediated cell to virus infection it is anti-
It answers, but the immunoregulatory activity of interferon gamma plays more in coordinating immune response and determining the long-term antiviral state of body
Important role, therefore interferon gamma has particularly important clinical value.
Seralbumin is the important component of blood plasma, is not easy to penetrate glomerulus under normal circumstances, internal distributed pole it is wide and
There is no zymetology and immunologic competence, is ideal pharmaceutical carrier.Albumin fusion technology has the advantage that:Albumin and target egg
It is linked in the cell by peptide bond through protein translation system in vain, is not required to additional extracorporeal treatment;The expression of albumin is higher,
The expression of destination protein can be improved after being merged with it;Albumin is one stable " inert protein ", after being merged with it
The stability of destination protein can be improved;Albumin fusion protein has longer drug half-life, by small molecular protein drug
It can be expected to improve half-life period in blood with Albumin fusion.Currently, in experimental animal after multiple protein and Albumin fusion
The extension of Half-life in vivo is confirmed.
The limitation of natural interferon and the current generally existing half-life short of artificial recombination interferon, half-life period are generally 2-4
A hour.Half-life short brings great inconvenience, the increase for the treatment of number of times, corresponding time cost and economic cost to treatment
Increase therewith, and the tenability limit of body is also possible to be broken the generation for leading to adverse reaction.The main reason for half-life short
There are two:The too small tachytrophism in vivo of molecular weight of interferon, interferon especially recombinant interferon affinity is poor to be exempted from
Epidemic disease system is removed.
And common long-acting interferon is using polyethylene glycol fused interferon as representative on the market, only in the level of molecular weight
Part solves the problems, such as that interferon molecule amount is small and leads to half-life short, while polyethylene glycol fused interferon cost is very
Height is unfavorable for clinically applying.
Invention content
In order to solve the above technical problems, the present invention provides one kind by bovine albumin, Bov IFN γ and Bov IFN α groups
At fusion protein and preparation method thereof, and thus fusion protein with after freeze drying protectant mixture, it is freeze-dried to be prepared into
To a kind of recombinant bovine long-acting interferon, the recombinant bovine long-acting interferon is remarkably improved the half-life period of Bov IFN, more commonly
The half-life period of Bov IFN improves 18 times or more, and has broad-spectrum disease resistance toxic action and can improve the immune response of Niu Zishen.
The technical solution that the present invention takes is:
A kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, the amino of the fusion protein
Acid sequence table is as shown in 400 < of SEQUENCE LISTING, 1 >.
The present invention also provides the gene for encoding above-mentioned fusion protein, the nucleotides sequence list such as SEQUENCE of the gene
Shown in 400 < of LISTING, 2 >, it is denoted as genome 1;Or as shown in 400 < of SEQUENCE LISTING, 3 >, it is denoted as genome 2.
Fusion protein described in 2 equal codified of the genome 1 and the genome.Genome 2 is the nucleosides to genome 1
Acid sequence optimize after as a result, when usual codon adaptation indexI CAI=1.0 be considered the gene in the expression system
In be optimal high efficient expression state, CAI values are lower to show that expression is lower in host.Most ideal point of G/C content in gene
Cloth ranging from 30~70% can influence translation and transcriptional efficiency in any region more than the range.It is sent out using software detection
Existing bovine albumin, ox IFN-γ, ox IFN-α original gene codon in Escherichia coli codon adaptation indexI (CAI) point
Not Wei 0.22,0.24,0.25, GC percentages be 42.9%, 39.8%, 58.2%;And by bovine albumin, ox IFN-γ,
It is 0.99,1.0,0.97, GC that each gene codon adaptation indexI (CAI) in Escherichia coli is obtained after ox IFN-α gene optimization
Percentage 49.9%, 44.8%, 54.6%.The utilization rate that low codon is significantly reduced by gene optimization avoids rare
Influence of the codon to protein expression, improves the G/C content of gene, improves transcription and translation efficiency.
The present invention also provides the expression vectors containing genome 1 or genome 2.
Further, the expression vector is the pET-32a coli expression carriers containing genome 1 or genome 2.
The present invention also provides the genetic engineering bacteriums containing genome 1 or genome 2.
Further, the genetic engineering bacterium is pET-32a/rAlb-IFN γ-IFN α.
Host cell containing genome 1 or genome 2 also belongs to protection scope of the present invention, further, the place
Chief cell is e. coli host cell, and further, the e. coli host cell is BL21 (DE3) competent cell
Or BL21 (DE3) competent cell with pGro7 plasmids.
The present invention also provides a kind of recombinant bovine long-acting interferon, the recombinant bovine long-acting interferon is by the fusion egg
In vain with after freeze drying protectant mixture, it is freeze-dried to form.
The freeze drying protectant is glycerine, mannitol and sucrose, is buffer solution, the final concentration of three with 10mmol/L PBS
For glycerine 100mL/L, mannitol 0.12g/mL and sucrose 0.025g/mL.
The invention also discloses the preparation methods of the fusion protein, and the preparation method comprises the following steps:It will contain
The expression vector of genome 1 or genome 2 is imported into e. coli host cell, obtains genetic engineering bacterium, genetic engineering bacterium
The crude product of the fusion protein is obtained after IPTG induced expressions, can be obtained fusion protein after purified.
The expression vector is the pET-32a coli expression carriers containing genome 1 or genome 2;
The genetic engineering bacterium is pET-32a/rAlb-IFN γ-IFN α, and preparation method is:
(1) design primer, obtained by reverse transcription or be manually respectively synthesized the bovine albumin with flexible linker sequences,
The target gene of Bov IFN γ, Bov IFN α;By flexible linker by bovine albumin, Bov IFN γ, Bov IFN α
Target gene connect, nucleotides sequence list such as 400 < of SEQUENCE LISTING, the 2 > institutes of the target gene after connection
Show or as shown in 400 < of SEQUENCE LISTING, 3 >;
(2) target gene after connection is connected on pET-32a plasmids and obtains expression vector;
(3) expression vector is imported into e. coli host cell, you can obtain genetic engineering bacterium pET-32a/rAlb-
IFNγ-IFNα。
The e. coli host cell is BL21 (DE3) competent cells or BL21 (DE3) senses with pGro7 plasmids
By state cell.
The method of the purifying is:The crude product of fusion protein is successively through affinity chromatography, anion-exchange chromatography and molecular sieve
Chromatographic purifying.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
The acquisition methods of the genome 1 are:
A. design of primers
The primer sequence of bovine albumin (Alb) is:
Upstream Alb-F1:CCGGAATTCATGAAGTGGGTGACTT carries EcoRI restriction enzyme sites;
Downstream Alb-R1:
ACCACCACCAGAACCACCACCACCGGCTAAGGCTGTTTG, with flexible linker;
The primer sequence of Bov IFN γ (IFN-γ) is:
Upstream IFN-γ-F1:
GGTGGTTCTGGTGGTGGTGGTTCTATGAAATATACAAGCTATTT, with flexible linker;
Downstream IFN-γ-R1:
ACCACCACCAGAACCACCACCACCCGTTGATGCTCTCCG, with flexible linker;
The primer sequence of Bov IFN α (IFN-α) is:
Upstream IFN-α-F1:
GGTGGTTCTGGTGGTGGTGGTTCTTGCCACCTGCCTC, with flexible linker;
Downstream IFN-α-R1:CCCTCGAGGTCCTTTCTCCTGAAAC carries XhoI restriction enzyme sites;
B. RNA is extracted from cattle liver, by reverse transcription obtain ox Alb, ox IFN-γ and ox IFN-α target gene,
The gene order of three respectively as shown in 400 < of SEQUENCE LISTING, 4 >, 400 < of SEQUENCE LISTING, 5 > and
Shown in 400 < of SEQUENCE LISTING, 6 >;
Respectively using the target gene of ox Alb, ox IFN-γ and ox IFN-α as template, and it is utilized respectively ox Alb, ox IFN-
The upstream and downstream primer of γ and ox IFN-α carry out PCR amplification, respectively obtain the ox Alb for connecting flexible linker, ox IFN-γ and
Ox IFN-α gene.
PCR reaction systems and condition are:In the overall reaction system of 25 μ L, 1.5 μ L of template ribonucleic acid, upstream and downstream primer is each
0.5 μ L, 2.5 μ L, dNTP Mix of reverse transcriptase are 10 μ L, add RNase Free water to 25 μ L;The reaction of the RT-PCR reactions
Condition is:50 DEG C of reverse transcriptions 30min, 95 DEG C of pre-degeneration 4min, into cycle;95 DEG C of denaturation 45s, 58 DEG C of annealing 45s, 72 DEG C are prolonged
1kb/min is stretched, is recycled 35 times, last 72 DEG C of extensions 10min.
C. rAlb-IFN γ genes are obtained using flexible linker connection ox Alb and ox IFN-γ target gene
The PCR reaction systems and reaction condition of connection be:In the overall reaction system of 25 μ L, connect flexible linker's
1 μ L of Alb gene templates DNA connect 1 μ L, Alb sense primer of IFN-γ template DNA 0.5 the μ L, IFN- of flexible linker
0.5 μ L, Taq archaeal dna polymerase of γ downstream primers, 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Connection
PCR reaction conditions are:95 DEG C of pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extension 1kb/
Min, totally 35 recycle;Last 72 DEG C of extensions 10min.
D. rAlb-IFN γ-IFN are obtained using flexible linker connections rAlb-IFN γ genes and ox IFN-α target gene
α genes
The PCR reaction systems and reaction condition of connection be:In the overall reaction system of 25 μ L, rAlb-IFN γ gene templates
1 μ L of DNA connect 1 μ L, Alb sense primer of IFN-α template DNA 0.5 the μ L, 0.5 μ of IFN-α downstream primer of flexible linker
2.5 μ L, dNTP Mix of L, Taq archaeal dna polymerase is 10 μ L, adds RNase Free water to 25 μ L;Connecting PCR reaction conditions is:95
DEG C pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, totally 35 recycle;Finally
72 DEG C of extension 10min.
Genome 2 is artificial synthesized gene after being optimized to genome 1, the acquisition methods of the genome 2
For:
A. design of primers
The primer sequence of bovine albumin (Alb) is:
Upstream Alb-F2:CGGGATCCATGAAATGGGTTACCTT carries BamHI restriction enzyme sites;
Downstream Alb-R2:
ACCACCACCAGAACCACCACCACCAGCCAGAGCGGTC, with flexible linker;
The primer sequence of Bov IFN γ (IFN-γ) is:
Upstream IFN-γ-F2:
GGTGGTTCTGGTGGTGGTGGTTCTATGAAATACACCTCTTAC, with flexible linker;
Downstream IFN-γ-R2:
ACCACCACCAGAACCACCACCACCGGTAGAAGCACGACG, with flexible linker;
Bov IFN α (IFN-α):
Upstream IFN-α-F2:
GGTGGTTCTGGTGGTGGTGGTTCTTGCCACCTGCCG, with flexible linker;
Downstream IFN-α-R2:
CCCTCGAGGTCTTTACGACGGAAA carries XhoI restriction enzyme sites.
B. the ox Alb, ox IFN-γ and ox IFN-α target gene, the gene order of three is respectively such as SEQUENCE
Shown in 400 < of LISTING, 7 >, 400 < of SEQUENCE LISTING 400 <, 8 > and SEQUENCE LISTING, 9 >;
Respectively using the target gene of ox Alb, ox IFN-γ and ox IFN-α as template, and it is utilized respectively ox Alb, ox IFN-
The upstream and downstream primer of γ and ox IFN-α carry out PCR amplification, respectively obtain the ox Alb for connecting flexible linker, ox IFN-γ and
Ox IFN-α gene.
PCR reaction systems and condition are:In the overall reaction system of 25 μ L, 1.0 μ L of genomic DNA, upstream and downstream primer is each
0.5 μ L, Taq archaeal dna polymerase, 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;The RT-PCR reactions
Reaction condition is:95 DEG C of pre-degeneration 4min, into cycle;95 DEG C of denaturation 45s, 60 DEG C of annealing 45s, 72 DEG C extend 1kb/min, follow
Ring 35 times, last 72 DEG C of extensions 10min.
C. rAlb-IFN γ genes are obtained using flexible linker connection ox Alb and ox IFN-γ target gene
The PCR reaction systems and reaction condition of connection be:In the overall reaction system of 25 μ L, connect flexible linker's
Alb gene template DNA1 μ L connect 1 μ L, Alb sense primer of IFN-γ template DNA, the 0.5 μ L of flexible linker, IFN-γ
0.5 μ L, Taq archaeal dna polymerase of downstream primer, 2.5 μ L, dNTP Mix is 10 μ L, adds RNase Free water to 25 μ L;Connect PCR
Reaction condition is:95 DEG C of pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, altogether
35 cycles;Last 72 DEG C of extensions 10min.
D. rAlb-IFN γ-are obtained using flexible linker connections rAlb-IFN γ genes and ox IFN-α target gene
IFN-α gene
The PCR reaction systems and reaction condition of connection be:In the overall reaction system of 25 μ L, rAlb-IFN γ gene templates
1 μ L of DNA, 1 μ L of IFN-α template DNA connect Alb the sense primers 0.5 μ L, 0.5 μ of IFN-α downstream primer of flexible linker
2.5 μ L, dNTP Mix of L, Taq archaeal dna polymerase is 10 μ L, adds RNase Free water to 25 μ L;Connecting PCR reaction conditions is:95
DEG C pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extension 1kb/min, totally 35 recycle;Finally
72 DEG C of extension 10min.
The present invention also provides the application of the recombinant bovine long-acting interferon, long half time had up to 72 hours or more
Broad-spectrum disease resistance toxic action and the immune response that Niu Zishen can be improved.
Compared with prior art, the present invention has the advantages that:
1. ox Alb, ox IFN-γ and ox IFN-α gene are realized amalgamation and expression by flexible linker, interference is improved
Plain half-life period improves 18 times or more compared with plain interferon;Compared with common polyethylene glycol fused interferon, significantly drop
Low cost.
2. by being optimized to ox Alb, ox IFN-γ and ox IFN-α gene, ox Alb, ox IFN-γ and ox are improved
The expression quantity of IFN-α fusion protein.
3. using recombination bacillus coli pET-32a/rAlb-IFN γ-IFN α as expression bacterial strain, by introducing molecular chaperones
PGro7 plasmids, in protein expression, generation inclusion body is less, forms great amount of soluble albumen, avoids inclusion body denaturation and answers
The process of property, substantially reduces the time of expressing fusion protein;
4. the fusion protein disclosed by the invention being made of ox Alb, ox IFN-γ and ox IFN-α not only has IFN-α
Broad-spectrum disease resistance toxic action, while significantly improving the immune response of Niu Zishen.
Description of the drawings
Fig. 1 is that bovine albumin gene, Bov IFN α genes and the Bov IFN γ genes RT-PCR in embodiment 1 are expanded
Result;Swimming lane M:DNA Marker DL2000;Swimming lane 1:Bov IFN α gene RT-PCR amplified productions;Swimming lane 2:Ox interferes
Plain γ genes RT-PCR amplified productions;Swimming lane 3:Bovine albumin gene RT-PCR amplified productions;
Fig. 2 be embodiment 1 in ox Alb, IFN-γ connected with the target gene of IFN-α after PCR amplification result;
Swimming lane M:DNA Marker DL10000;Swimming lane 1:Bovine albumin gene, Bov IFN γ genes are connect with Bov IFN α genes
Amplified production;
Fig. 3 is the PCR amplification and double digestion qualification result of the positive colony plasmid in embodiment 1;Swimming lane M:DNA
Marker DL10000;Swimming lane 1:Recombinant plasmid double digestion result;Swimming lane 2:Plasmid PCR result;
Fig. 4 is the SDS-PAGE electrophoretic examinations results of the recombinant protein in embodiment 1;Swimming lane M:Albumen Marker;Swimming lane
1:Supernatant after bacterial cell disruption after recombinant bacterium induction;Swimming lane 2:It is precipitated after bacterial cell disruption after recombinant bacterium induction;Swimming lane 3:It is unloaded
Control;
Fig. 5 is the Western Blot qualification results for the fusion protein that embodiment 1 obtains;Swimming lane M:Albumen Marker;Swimming
Road 1:Supernatant after recombinant bacterium induction is broken;Swimming lane 2:It is precipitated after being crushed for recombinant bacterium induction;
Fig. 6 is that the recombinant bovine long-acting interferon α made from the fusion protein in embodiment 1 causes cell to VSV in embodiment 5
The inhibiting effect of lesion;1 is VSV virus control wells;2 be HEp-2 cell control wells;A3-12 is gradient dilution (from right to left)
Human interferon standard items handle hole;B3-12 is that the recombinant bovine long-acting interferon α of gradient dilution (from right to left) handles hole;
Fig. 7 is the recombinant bovine long-acting interferon α intramuscular injection blood made from the fusion protein in embodiment 1 in embodiment 8
Concentration-time changing curve.
Specific implementation mode
Embodiment 1
A kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, preparation method are as follows:
1. the acquisition of bovine albumin (Alb), Bov IFN γ (IFN-γ) and Bov IFN α (IFN-α) target gene with
Amplification
Design of primers:
It is shown in Table 1 according to the objective gene sequence design synthetic primer reported in Genebank, in the upstream of bovine albumin
EcoRI restriction enzyme sites and Linker sequences are introduced in primer and downstream primer respectively, Bov IFN γ sense primer and under
Linker sequences are introduced respectively in trip primer, introduce Linker sequences respectively in the sense primer of Bov IFN α and downstream primer
Row and XhoI restriction enzyme sites.
1 PCR amplification primer of table
RT-PCR obtains target gene:
RNA is extracted from cattle liver tissue, passes through reverse transcription acquisition ox Alb, the purpose base of ox IFN-γ and ox IFN-α
Cause, the gene order of three respectively such as 400 < of SEQUENCE LISTING, 4 >, 400 < of SEQUENCE LISTING, 5 > and
Shown in 400 < of SEQUENCE LISTING, 6 >;
RT-PCR reaction systems (25 μ L) are shown in Table 2
2 RT-PCR reaction systems of table
RNase Free water | 10μL |
dNTP Mix | 10μL |
Reverse transcriptase | 2.5μL |
Upstream and downstream primer | Each 0.5 μ L |
Geneome RNA | 1.5μL |
Response parameter is:50 DEG C of reverse transcriptions 30min, 95 DEG C of pre-degeneration 4min, into cycle:95 DEG C of denaturation 45s;58 DEG C are moved back
Fiery 45s, 72 DEG C of extension 1kb/min, totally 35 recycle;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 1850bp, 560bp and 530bp or so in RT-PCR amplified productions,
The results are shown in Figure 1 for it, illustrate to be prepared respectively the ox Alb for being separately connected flexible linker sequences, ox IFN-γ and
The target gene of ox IFN-α.
2. the connection of target gene
Target gene is diluted to 10ug/mL, connects each section of target gene using over-lap PCR, 25 μ L reaction systems are such as
Shown in table 3, table 4:
3 rAlb-IFN γ PCR reaction systems of table
4 rAlb-IFN γ of table-IFN α PCR reaction systems
Response parameter is:95 DEG C of pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;58 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 recycle;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 2880bp or so in pcr amplification product, and the results are shown in Figure 2,
Occur rAlb-IFN γ and IFN-α amplified production band in Fig. 2, this is because being connected with IFN-α gene in rAlb-IFN γ
During, there is non-specific responding.The nucleotide sequence of obtained target gene such as 400 < of SEQUENCE LISTING, 2 >
It is shown.
3. expression vector establishment
After sequencing is errorless, PCR glue recovery product uses target gene after selection connection with pET-32a plasmids
EcoRI and XhoI restriction enzymes carry out double digestion and recycling, and double digestion is done by 20 μ L systems in table 5:
5 double digestion system of table
General buffer | 2μL |
Restriction enzyme (a pair) | 1μL+1μL |
Carrier or recycling segment | 2ul |
RNase Free water | 14μL |
The digestion recovery product of target gene and pET-32a plasmids after connection is attached by the system in table 6,4
DEG C overnight connection:
6 enzyme disjunctor system of table
Target fragment DNA | 10μL |
Expression vector | 3μL |
buffer | 2μL |
Ligase | 1μL |
RNase Free water | 4μL |
It converts in connection product to e. coli bl21 (DE3) competent cell, competent cell is coated on benzyl containing ammonia
The LB culture medium flat plates of penicillin are incubated overnight;Single bacterium colony on picking LB tablets carries out target gene PCR identifications, positive colony
Bacteria plasmid is identified through EcoRI and XhoI double digestions, is accredited as positive and is indicated that engineering bacteria is built successfully, PCR amplification and double digestion
Product detects single band through agarose gel electrophoresis at 2880bp, and the results are shown in Figure 3, illustrates successfully to obtain
PET-32a/rAlb-IFN γ-IFN α engineering bacteria.
4. the expression of recombinant protein
Picking engineering bacteria 37 DEG C of shaking table recovery 1h in the LB culture mediums containing 100 μ g/ml ampicillins, in LB culture mediums
Amplification culture 4h (OD=1.0) in (the 100 μ g/ml containing ampicillin), is added the IPTG of final concentration of 100 μ g/ml, 32 DEG C lure
Lead expression 5h;Thalline is collected, through SDS-PAGE electrophoresis detections, the results are shown in Figure 4, it can be seen from the figure that recombinant bacterium lures
Supernatant is deposited in the visible predominant expression band in the places 123.8KD or so after leading the bacterial cell disruption after 5h, illustrates in precipitation and supernatant
In equal successful expression fusion proteins.
Mass volume ratio 1 is added:Precipitation is resuspended in 1 PBS;- 20 DEG C precipitate 3 times in room temperature multigelation;4 DEG C of ultrasound cracking
Bacterial precipitation, work 10s, is spaced 3S, ultrasonic 6min, and whole process repeats 3~4 times;4 DEG C, 12000r/min centrifuges 15min,
Supernatant, inclusion body (inclusion body is through dissolving, refolding strategy) are taken respectively, obtain crude fusion protein.
5. fusion protein purification
5.1His affinity chromatography
After membrane filtration of the crude fusion protein with 0.22 μm of aperture, loading is by being connected to AKTA explorer 100
On protein purification system, the His affinity columns balanced with Binding Buffer I (PBS) are washed away not with PBS buffer solution
In conjunction with albumen, until A280nm stablizes, then with Elution buffer I (50mM trishydroxymethylaminomethanes, 20~500mM
Imidazoles, PH8.0) elution, collect rAlb-IFN γ-IFN α protein peak.
5.2DEAE anion-exchange chromatography
By the albumen collected after His affinitive layer purifications displacement to (the 50mM trihydroxy methyls of Binding Buffer II
Aminomethane, PH6.5) in after, loading by the DEAE anion exchange chromatography that has been balanced with Binding Buffer II, then
After crossing column to A280nm value stabilizations with Binding Buffer II, with (the 50mM trihydroxy methyl amino first of Elution Buffer II
Alkane, 1M NaCl, PH6.5) linear gradient elution, collect rAlb-IFN γ-IFN α protein peak.
5.3 sieve chromatography
Loading is by with III (50mM of Binding Buffer after the sample concentration that ion-exchange chromatography is collected into
Na2HPO4,0.15M NaCl, PH7.4) 200 molecular sieve chromatographies of Superdex have been balanced, it is washed with Binding Buffer III
It is de-, collect rAlb-IFN γ-IFN α protein peak.
5.4 sample identification
Measure rAlb-IFN γ-IFN α potency and specific activity, specific activity >=107U/mg, albumen are qualified;It is aseptic subpackaged, -80
DEG C preserve.The fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α is can be obtained, amino acid sequence is such as
Shown in 400 < of SEQUENCE LISTING, 1 >.
Embodiment 2
A kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, other are with embodiment 1, only
E. coli bl21 therein (DE3) competent cell is replaced in order to which BL21 (DE3) competence with pGro7 plasmids is thin
Born of the same parents.The SDS-PAGE electrophoresis results of its fusion protein are compareed with embodiment 1,123.8KD or so place's predominant expression items in supernatant
Band is thicker, illustrates after introducing molecular chaperones pGro7, expression of the destination protein in supernatant is more preferable, obtained fusion protein amount
Higher.The albumen of Bacillus coli expression is mostly present in inclusion body;By introducing molecular chaperones in expressing bacterial strain, cooperate with
Expression albumen correctly folds, and reaches solubility expression of protein.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
Embodiment 3
A kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, preparation method are as follows:
1. the acquisition of bovine albumin (Alb), Bov IFN γ (IFN-γ) and Bov IFN α (IFN-α) target gene with
Amplification
Ox Alb, ox IFN-γ and ox IFN-α in embodiment 1 is optimized, artificial synthesized ox Alb, ox IFN-γ and
Ox IFN-α target gene, after optimization, the nucleotide sequence of three is respectively such as 400 < of SEQUENCE LISTING 7 >, SEQUENCE
Shown in 400 < of LISTING 400 <, 8 > and SEQUENCE LISTING, 9 >.
1.1 codon optimization
Genetic codon has 64 kinds, but most biological tendencies are in utilizing the part in these codons.Those
By the most frequent referred to as best codon (optimal codons) utilized, what those were not frequently utilized that is known as rare or utilizes
The low codon of rate (rare or low-usage codons).In fact, common each biology for doing protein expression or production
(including Escherichia coli, yeast, mammalian cell, plant cell and insect cell) all shows the profit of codon to a certain degree
Difference or preference.The expression efficiency of the gene containing best codon is apparently higher than in Escherichia coli, yeast and drosophila and is contained
The expression efficiency of the gene of the codon of poor efficiency.Therefore, in heterologous expression system, the preferences of codon are largely
On affect the expression of recombinant protein.Using preference codon (preferred codons) and avoid utilizing rare codon
Gene chemical synthesis is carried out, the redesign of this gene is codon optimization.Therefore, in the present embodiment to ox Alb, ox IFN-γ and
Ox IFN-α gene codon optimizes.
Interpretation of result after 1.2 codon optimizations
It is optimal efficient in the expression system to be considered the gene when usual codon adaptation indexI (CAI)=1.0
Expression status, CAI values are lower to show that expression is lower in host.G/C content most ideal distribution ranging from 30 in gene~
70%, in any region translation and transcriptional efficiency can be influenced more than the range.Ox Alb, ox are found using software detection
The codon of IFN-γ and ox IFN-α original gene codon adaptation indexI (CAI) in Escherichia coli is respectively 0.22,
0.24,0.25, GC percentages are 42.9%, 39.8%, 58.2%;And by ox Alb, ox IFN-γ and ox IFN-α gene
Obtained after optimization recombination codon adaptation indexI (CAI) in Escherichia coli be respectively 0.99,1.0,0.97, GC percentages
49.9%, 44.8%, 54.6%.The utilization rate that low codon is significantly reduced by gene optimization, avoids rare codon
Influence to protein expression improves the G/C content of gene, improves transcription and translation efficiency, and then improves the table of recombinant protein
Up to amount.
1.3 design of primers:
7 PCR amplification primer of table
The genomic DNA of ox Alb, ox IFN-γ and ox IFN-α after optimization are diluted to 0.05mg/mL respectively.It utilizes
PCR amplification obtains target gene, and 25 μ L reaction systems are as shown in table 8:
8 PCR reaction systems of table
Response parameter is:95 DEG C of pre-degeneration 4min, into cycle:95 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 recycle;Last 72 DEG C of extensions 10min.
Ox Alb, ox IFN-γ and ox IFN-α pcr amplification product through agarose gel electrophoresis respectively 1850bp,
There is specific band in 560bp and 530bp or so, illustrate that the ox for being separately connected flexible linker after optimization has been prepared
The target gene of Alb, ox IFN-γ and ox IFN-α.
2. the connection of target gene
Target gene is diluted to 10ug/mL, connects each section of target gene using over-lap PCR, 25 μ L reaction systems are such as
Shown in table 9, table 10:
9 rAlb-IFN γ PCR reaction systems of table
10 rAlb-IFN γ of table-IFN-α PCR reaction systems
Response parameter is:95 DEG C of pre-degeneration 4min, into cycle:94 DEG C of denaturation 45s;60 DEG C of annealing 45s, 72 DEG C of extensions
1kb/min, totally 35 recycle;Last 72 DEG C of extensions 10min.
There is specific band through agarose gel electrophoresis in 2880bp or so in pcr amplification product, illustrates successfully to be connected
RAlb-IFN γ-IFN-α gene after connecing.The nucleotide sequence of obtained target gene such as SEQUENCE LISTING 400
Shown in 3 > of <.
3. expression vector establishment
The glue recovery product of target gene PCR errorless after sequencing after selection connection is used with pET-32a plasmids
BamHI, XhoI restriction enzyme carry out double digestion and recycling, and double digestion is done by 20 μ L systems in table 11:
11 double digestion system of table
General buffer | 2μL |
Restriction enzyme (a pair) | 1μL+1μL |
Carrier or recycling segment | 2ul |
RNase Free water | 14μL |
The digestion recovery product of target gene and pET-32a plasmids after connection is attached by the system in table 12,4
DEG C overnight connection:
Table 12
Target fragment DNA | 10μL |
Expression vector | 3μL |
buffer | 2μL |
Ligase | 1μL |
RNase Free water | 4μL |
It converts in connection product to e. coli bl21 (DE3) competent cell, competence is coated on the mould of benzyl containing ammonia
It is incubated overnight in the LB tablets of element;The bacterium colony grown on LB tablets is taken to identify target gene, positive colony bacteria plasmid warp through PCR
BamHI, XhoI double digestion are identified, are accredited as positive and are indicated expression vector establishment success, PCR amplification and double digestion product are through fine jade
There is single band at the places 2880bp or so in sepharose electrophoresis, illustrates containing rAlb-IFN γ-IFN α fusion gene engineering bacterium
PET-32a/rAlb-IFN γ-IFN α is built successfully.
4. the expression of recombinant protein
Picking engineering bacteria 37 DEG C of shaking table recovery 1h in the LB culture mediums containing 100 μ g/ml ampicillins, in LB culture mediums
Amplification culture 4h (OD=1.0) in (the 100 μ g/ml containing ampicillin), is added the IPTG of final concentration of 100 μ g/ml, 32 DEG C lure
Lead expression 5h;Thalline is collected, through SDS-PAGE electrophoresis detections, supernatant is deposited in after the bacterial cell disruption after recombinant bacterium induction 5h
The visible predominant expression band in the places 123.8KD or so illustrates to have obtained recombinant protein in supernatant precipitates.
Mass volume ratio 1 is added:Precipitation is resuspended in 1 PBS;- 20 DEG C precipitate 3 times in room temperature multigelation;4 DEG C of ultrasound cracking
Bacterial precipitation, work 10s, is spaced 3S, ultrasonic 6min, and whole process repeats 3~4 times;4 DEG C, 12000r/min centrifuges 15min,
Supernatant, inclusion body (inclusion body is through dissolving, refolding strategy) are taken respectively, obtain crude fusion protein.
5. fusion protein purification
5.1His affinity chromatography
After membrane filtration of the crude fusion protein with 0.22 μm of aperture, loading is by being connected to AKTA explorer 100
On protein purification system, the His affinity columns balanced with Binding Buffer I (PBS) are washed away not with PBS buffer solution
In conjunction with albumen, until A280nm stablizes, then with Elution buffer I (50mM trishydroxymethylaminomethanes, 20~500mM
Imidazoles, PH8.0) elution, collect rAlb-IFN γ-IFN α protein peak.
5.2DEAE anion-exchange chromatography
By the albumen collected after His affinitive layer purifications displacement to (the 50mM trihydroxy methyls of Binding Buffer II
Aminomethane, PH6.5) in after, loading by the DEAE anion exchange chromatography that has been balanced with Binding Buffer II, then
After crossing column to A280nm value stabilizations with Binding Buffer II, with (the 50mM trihydroxy methyl amino first of Elution Buffer II
Alkane, 1M NaCl, PH6.5) linear gradient elution, collect rAlb-IFN γ-IFN α protein peak.
5.3 sieve chromatography
Loading is by with Binding Buffer III after the sample concentration that ion-exchange chromatography is collected into
(50mMNa2HPO4,0.15M NaCl, PH7.4) 200 molecular sieve chromatographies of Superdex have been balanced, with Binding Buffer
III elution, collects rAlb-IFN γ-IFN α protein peak.
5.4 sample identification
Measure rAlb-IFN γ-IFN α potency and specific activity, specific activity >=107U/mg, albumen are qualification;It is aseptic subpackaged ,-
80 DEG C of preservations.It can be obtained the fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, amino acid sequence
As shown in 400 < of SEQUENCE LISTING, 1 >.
Embodiment 4
A kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, other are with embodiment 3, only
E. coli bl21 therein (DE3) competent cell is replaced in order to which BL21 (DE3) competence with pGro7 plasmids is thin
Born of the same parents.The SDS-PAGE electrophoresis results of its fusion protein are compareed with embodiment 3,123.8KD or so place's predominant expression items in supernatant
Band is thicker, illustrates after introducing molecular chaperones pGro7, expression of the destination protein in supernatant is more preferable, obtained fusion protein amount
Higher.The albumen of Bacillus coli expression is mostly present in inclusion body;By introducing molecular chaperones in expressing bacterial strain, cooperate with
Expression albumen correctly folds, and reaches solubility expression of protein.
Described BL21 (DE3) competent cell with pGro7 plasmids is purchased from Shanghai Jinan Technology Co., Ltd./glad hundred promise
Biology, article No. V205.
Embodiment 5
A kind of recombinant bovine long-acting interferon α, by the fusion protein in embodiment 1,2,3,4 respectively with freeze drying protectant mixture
Later, freeze-dried to form.The freeze drying protectant is glycerine, mannitol and sucrose, is buffer solution with 10mmol/L PBS,
Final concentration of glycerine 100mL/L, mannitol 0.12g/mL and the sucrose 0.025g/mL of three.
Embodiment 6
Examples 1 to 4 is obtained by the identification of bovine albumin, Bov IFN γ and Bov IFN the α fusion protein formed
The quantitative detection of 6.1 protein contents
With Lowry methods, the standard protein that institute is examined and determine with Chinese food pharmaceutical biological product is made standard test, measures embodiment
1~4 obtained fusion protein concentration is all higher than 1.1mg/ml.
6.2SDS-PAGE electrophoresis detection
Compared with empty bacterium, fusion protein has the newly-increased protein band of a dense dye in 123.8KD or so, as shown in Figure 4.
6.3Western Blot results
Fusion protein in Examples 1 to 4 is detected respectively, with the anti-ox alpha interferon of abcam companies mouse (1:5000 dilutions) it is one
It is anti-, using goat anti-mouse IgG-HRP as secondary antibody (1:10000 dilutions).Recombinant bovine long-acting interferon sample can be with anti-Bov IFN α
Specific reaction occurs for monoclonal antibody, and specific band occur in the places 123.8KD or so, as shown in Figure 5.
Embodiment 7
Bioactivity freeze-dried four parts of recombinant bovine long-acting interferon α in embodiment 5
Inhibit method according to few cells lesion, Hep-2 cells are made into 5 × 10 with culture medium5Cell/ml cells suspend
Liquid, per hole, inoculation 0.1ml moves into 96 porocyte culture plates.37 DEG C, 5%CO2For 24 hours, the recombinant bovine that various dose is added is long for culture
Interferon-' alpha ' is imitated, inhales abandon afterwards for 24 hours, then inoculation 100TCID50VSV viruses respectively.
Test result
The result shows that the recombinant bovine long-acting interferon α obtained causes the lesion of HEp-2 cells to have apparent inhibit VSV
Effect.The lesions such as occurs cell rounding after untreated cell inoculation virus, falls off, is disintegrated.And the recombinant bovine obtained is long
After imitating interferon treated cell inoculation virus, it is observed continuously under inverted microscope, cellular morphology is normal, does not occur any
Lesion measures potency >=107U/ml, as shown in Figure 6.
Embodiment 8
The four parts of recombinant bovine long-acting interferon α freeze-dryings obtained respectively by the fusion protein of Examples 1 to 4 in embodiment 5
The measurement of half-life period of the agent (being denoted as A, B, C, D respectively) in ox body
Cytopathic-effect inhibition assay measures the blood concentration and time relationship of rAlb-IFN γ-IFN α
Take the ox (half male and half female) that six weight are roughly the same, neck that 2mg/ml recombinant bovine long-acting interferons α is subcutaneously injected
Freeze-dried 2ml, respectively in 1h, 2h, 4h, 8h, 16h, 26h, 44h, 79h venous blood collection, 4 DEG C of solidifications of blood sample, 3500rpm low temperature from
Heart 10min detaches serum, and every ox blood sample of each time point is to be measured in -20 DEG C of preservations.Serum sample is measured using cytopathic-effect inhibition assay
The concentration of rAlb-IFN γ-IFN α in product is carried out curve fitting and calculating parameter with DAS pharmacokinetics softwares.Parameter result of calculation
It is shown in Table 13.
Dominant dynamic parameters in serum after 13 recombinant bovine long-acting interferon α intramuscular injection of table
The result shows that recombinant bovine long-acting interferon α has longer half-life period.Half-life period can reach 72h or so after measured, compared with
Plain interferon improves about 18 times.
Embodiment 9
The freeze-dried measurement that ox cellullar immunologic response is influenced of four parts of recombinant bovine long-acting interferon α in embodiment 5
It takes six roughly the same beef cattles of weight to be divided into two groups, is denoted as experimental group and control group;Experimental group neck is subcutaneously noted
The 2mg/ml recombinant bovine long-acting interferon freeze-dried 2ml of α are penetrated, the PBS of 2mL is subcutaneously injected in control group neck, takes after injecting 4 weeks outside ox
All blood takes weekly a blood later, detaches lymphocyte using lymphocyte separation medium, lymphocyte passes through serum-free RPMI
It after 1640 culture mediums wash 2 times, is resuspended with complete medium, adjustment cell concentration is 2 × 106A/ml, 24 porocyte culture plates are every
Hole addition 1ml lymphocytes, 37 DEG C, 5%CO272h is cultivated, supernatant when collecting lymphocyte culture.ELISA detects culture supernatant
Middle IL-2, IL-4 content, is carried out by kit specification, and testing result is as shown in table 14:
Table 14 ELISA detection each group ox cellullar immunologic responses are horizontal
The result shows that after injection recombinant bovine long-acting interferon α, can significantly improve ox Evaluation of Cytokines in Peripheral Blood IL-2,
The content of IL-4 enhances cellullar immunologic response level, significantly improves immunity level.
It is above-mentioned with reference to embodiment to a kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α and
The detailed description that preparation method carries out is illustrative without being restrictive, and can be enumerated according to limited range several
A embodiment, therefore the change and modification in the case where not departing from present general inventive concept, should belong within protection scope of the present invention.
SEQUENCE LISTING
<110>Wuhu Co., Ltd of Ying Tefeier biological products industrial research institute
<120>A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α
<130> 1
<160> 9
<170> PatentIn version 3.3
<210> 1
<211> 959
<212> PRT
<213>Bovine albumin-interferon gamma-interferon alpha fusion protein
<400> 1
Met Lys Trp Val Thr Phe Ile Ser Leu Leu Leu Leu Phe Ser Ser Ala
1 5 10 15
Tyr Ser Arg Gly Val Phe Arg Arg Asp Thr His Lys Ser Glu Ile Ala
20 25 30
His Arg Phe Lys Asp Leu Gly Glu Glu His Phe Lys Gly Leu Val Leu
35 40 45
Ile Ala Phe Ser Gln Tyr Leu Gln Gln Cys Pro Phe Asp Glu His Val
50 55 60
Lys Leu Val Asn Glu Leu Thr Glu Phe Ala Lys Thr Cys Val Ala Asp
65 70 75 80
Glu Ser His Ala Gly Cys Glu Lys Ser Leu His Thr Leu Phe Gly Asp
85 90 95
Glu Leu Cys Lys Val Ala Ser Leu Arg Glu Thr Tyr Gly Asp Met Ala
100 105 110
Asp Cys Cys Glu Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Ser
115 120 125
His Lys Asp Asp Ser Pro Asp Leu Pro Lys Leu Lys Pro Asp Pro Asn
130 135 140
Thr Leu Cys Asp Glu Phe Lys Ala Asp Glu Lys Lys Phe Trp Gly Lys
145 150 155 160
Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu
165 170 175
Leu Leu Tyr Tyr Ala Asn Lys Tyr Asn Gly Val Phe Gln Glu Cys Cys
180 185 190
Gln Ala Glu Asp Lys Gly Ala Cys Leu Leu Pro Lys Ile Glu Thr Met
195 200 205
Arg Glu Lys Val Leu Ala Ser Ser Ala Arg Gln Arg Leu Arg Cys Ala
210 215 220
Ser Ile Gln Lys Phe Gly Glu Arg Ala Leu Lys Ala Trp Ser Val Ala
225 230 235 240
Arg Leu Ser Gln Lys Phe Pro Lys Ala Glu Phe Val Glu Val Thr Lys
245 250 255
Leu Val Thr Asp Leu Thr Lys Val His Lys Glu Cys Cys His Gly Asp
260 265 270
Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys
275 280 285
Asp Asn Gln Asp Thr Ile Ser Ser Lys Leu Lys Glu Cys Cys Asp Lys
290 295 300
Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Lys Asp Ala
305 310 315 320
Ile Pro Glu Asn Leu Pro Pro Leu Thr Ala Asp Phe Ala Glu Asp Lys
325 330 335
Asp Val Cys Lys Asn Tyr Gln Glu Ala Lys Asp Ala Phe Leu Gly Ser
340 345 350
Phe Leu Tyr Glu Tyr Ser Arg Arg His Pro Glu Tyr Ala Val Ser Val
355 360 365
Leu Leu Arg Leu Ala Lys Glu Tyr Glu Ala Thr Leu Glu Glu Cys Cys
370 375 380
Ala Lys Asp Asp Pro His Ala Cys Tyr Ser Thr Val Phe Asp Lys Leu
385 390 395 400
Lys His Leu Val Asp Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Asp
405 410 415
Gln Phe Glu Lys Leu Gly Glu Tyr Gly Phe Gln Asn Ala Leu Ile Val
420 425 430
Arg Tyr Thr Arg Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu
435 440 445
Val Ser Arg Ser Leu Gly Lys Val Gly Thr Arg Cys Cys Thr Lys Pro
450 455 460
Glu Ser Glu Arg Met Pro Cys Thr Glu Asp Tyr Leu Ser Leu Ile Leu
465 470 475 480
Asn Arg Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Glu Lys Val
485 490 495
Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser
500 505 510
Ala Leu Thr Pro Asp Glu Thr Tyr Val Pro Lys Ala Phe Asp Glu Lys
515 520 525
Leu Phe Thr Phe His Ala Asp Ile Cys Thr Leu Pro Asp Thr Glu Lys
530 535 540
Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Leu Lys His Lys Pro
545 550 555 560
Lys Ala Thr Glu Glu Gln Leu Lys Thr Val Met Glu Asn Phe Val Ala
565 570 575
Phe Val Asp Lys Cys Cys Ala Ala Asp Asp Lys Glu Ala Cys Phe Ala
580 585 590
Val Glu Gly Pro Lys Leu Val Val Ser Thr Gln Thr Ala Leu Ala Gly
595 600 605
Gly Gly Gly Ser Gly Gly Gly Gly Ser Met Lys Tyr Thr Ser Tyr Phe
610 615 620
Leu Ala Leu Leu Leu Cys Gly Leu Leu Gly Phe Ser Gly Ser Tyr Gly
625 630 635 640
Gln Gly Gln Phe Phe Arg Glu Ile Glu Asn Leu Lys Glu Tyr Phe Asn
645 650 655
Ala Ser Ser Pro Asp Val Ala Lys Gly Gly Pro Leu Phe Ser Glu Ile
660 665 670
Leu Lys Asn Trp Lys Asp Glu Ser Asp Lys Lys Ile Ile Gln Ser Gln
675 680 685
Ile Val Ser Phe Tyr Phe Lys Leu Phe Glu Asn Leu Lys Asp Asn Gln
690 695 700
Val Ile Gln Arg Ser Met Asp Ile Ile Lys Gln Asp Met Phe Gln Lys
705 710 715 720
Phe Leu Asn Gly Ser Ser Glu Lys Leu Glu Asp Phe Lys Lys Leu Ile
725 730 735
Gln Ile Pro Val Asp Asp Leu Gln Ile Gln Arg Lys Ala Ile Asn Glu
740 745 750
Leu Ile Lys Val Met Asn Asp Leu Ser Pro Lys Ser Asn Leu Arg Lys
755 760 765
Arg Lys Arg Ser Gln Asn Leu Phe Arg Gly Arg Arg Ala Ser Thr Gly
770 775 780
Gly Gly Gly Ser Gly Gly Gly Gly Ser Cys His Leu Pro His Thr His
785 790 795 800
Ser Leu Ala Asn Arg Arg Val Leu Met Leu Leu Gly Gln Leu Arg Arg
805 810 815
Val Ser Pro Ser Ser Cys Leu Gln Asp Arg Asn Asp Phe Ala Phe Pro
820 825 830
Gln Glu Ala Leu Gly Gly Ser Gln Leu Gln Lys Ala Gln Ala Ile Ser
835 840 845
Val Leu His Glu Val Thr Gln His Thr Phe Gln Leu Phe Ser Thr Glu
850 855 860
Gly Ser Ala Thr Thr Trp Asp Glu Ser Leu Leu Asp Lys Leu Arg Ala
865 870 875 880
Ala Leu Asp Gln Gln Leu Thr Asp Leu Gln Ala Cys Leu Arg Gln Glu
885 890 895
Glu Glu Leu Gln Gly Ala Pro Leu Leu Lys Glu Asp Ser Ser Leu Ala
900 905 910
Val Arg Lys Tyr Phe His Arg Leu Thr Leu Tyr Leu Gln Glu Lys Lys
915 920 925
His Ser Pro Cys Ala Trp Glu Val Val Arg Ala Gln Val Met Arg Ala
930 935 940
Phe Ser Ser Ser Thr Asn Leu Gln Glu Ser Phe Arg Arg Lys Asp
945 950 955
<210> 2
<211> 2877
<212> DNA
<213>Genome 1
<400> 2
atgaagtggg tgacttttat ttctcttctc cttctcttca gctctgctta ttccaggggt 60
gtgtttcgtc gagatacaca caagagtgag attgctcatc ggtttaaaga tttgggagaa 120
gaacatttta aaggcctggt actgattgcc ttttctcagt atctccagca gtgtccattt 180
gatgagcatg taaaattagt gaacgaacta actgagtttg caaaaacatg tgttgctgat 240
gagtcccatg ccggctgtga aaagtcactt cacactctct ttggagatga attgtgtaaa 300
gttgcatccc ttcgtgaaac ctatggtgac atggctgact gctgtgagaa acaagagcct 360
gaaagaaatg aatgcttcct gagccacaaa gatgatagcc cagacctccc taaattgaaa 420
ccagacccca atactttgtg tgatgagttt aaggcagatg aaaagaagtt ttggggaaaa 480
tacctatacg aaattgctag aagacatccc tacttttatg caccagaact cctttactat 540
gctaataaat ataatggagt ttttcaagaa tgctgccaag ctgaagataa aggtgcctgc 600
ctgctaccaa agattgaaac tatgagagaa aaggtactag cttcatctgc cagacagaga 660
ctcaggtgtg ccagtattca aaaatttgga gaaagagctt taaaagcatg gtcagtagct 720
cgcctgagcc agaaatttcc caaggctgag tttgtagaag ttaccaagct agtgacagat 780
ctcacaaaag tccacaagga atgctgccat ggtgacctac ttgaatgcgc agatgacagg 840
gcagatcttg ccaagtacat atgtgataat caagatacaa tctccagtaa actgaaggaa 900
tgctgtgata agcctttgtt ggaaaaatcc cactgcattg ctgaggtaga aaaagatgcc 960
atacctgaaa acctgccccc attaactgct gactttgctg aagataagga tgtttgcaaa 1020
aactatcagg aagcaaaaga tgccttcctg ggctcgtttt tgtatgaata ttcaagaagg 1080
catcctgaat atgctgtctc agtgctattg agacttgcca aggaatatga agccacactg 1140
gaggaatgct gtgccaaaga tgatccacat gcatgctatt ccacagtgtt tgacaaactt 1200
aagcatcttg tggatgagcc tcagaattta atcaaacaaa actgtgacca attcgaaaaa 1260
cttggagagt atggattcca aaatgcgctc atagttcgtt acaccaggaa agtaccccaa 1320
gtgtcaactc caactctcgt ggaggtttca agaagcctag gaaaagtggg tactaggtgt 1380
tgtacaaagc cggaatcaga aagaatgccc tgtactgaag actatctgag cttgatcctg 1440
aaccggttgt gcgtgctgca tgagaagaca ccagtgagtg aaaaagtcac caagtgctgc 1500
acagagtcat tggtgaacag acggccatgt ttctctgctc tgacacctga tgaaacatat 1560
gtacccaaag cctttgatga gaaattgttc accttccatg cagatatatg cacacttccc 1620
gatactgaga aacaaatcaa gaaacaaact gcacttgttg agctgttgaa acacaagccc 1680
aaggcaacag aggaacaact gaaaaccgtc atggagaatt ttgtggcttt tgtagacaag 1740
tgctgtgcag ctgatgacaa agaagcctgc tttgctgtgg agggtccaaa acttgttgtt 1800
tcaactcaaa cagccttagc cggtggtggt ggttctggtg gtggtggttc tatgaaatat 1860
acaagctatt tcttagcttt actgctctgt gggcttttgg gtttttctgg ttcttatggc 1920
cagggccaat tttttagaga aatagaaaac ttaaaggagt attttaatgc aagtagccca 1980
gatgtagcta agggtgggcc tctcttctca gaaattttga agaattggaa agatgaaagt 2040
gacaaaaaaa ttattcagag ccaaattgtc tccttctact tcaaactctt tgaaaacctc 2100
aaagataacc aggtcattca aaggagcatg gatatcatca agcaagacat gtttcagaag 2160
ttcttgaatg gcagctctga gaaactggag gacttcaaaa agctgattca aattccggtg 2220
gatgatctgc agatccagcg caaagccata aatgaactca tcaaagtgat gaatgacctg 2280
tcaccaaaat ctaacctcag aaagcggaag agaagtcaga atctctttcg aggccggaga 2340
gcatcaacgg gtggtggtgg ttctggtggt ggtggttctt gccacctgcc tcacacccac 2400
agcctggcca acaggagggt cctgatgctc ctgggacaac tgaggagggt ctccccttcc 2460
tcctgcctgc aggacagaaa tgacttcgca ttcccccagg aggcgctggg tggcagccag 2520
ttgcagaagg ctcaagccat ctctgtgctc cacgaggtga cccagcacac cttccagctt 2580
ttcagcacag agggctcggc cactacgtgg gatgagagcc tcctggacaa gctccgcgct 2640
gcactggatc agcagctcac tgacctgcaa gcctgtctga ggcaggagga ggagctgcaa 2700
ggagctcccc tgctcaagga ggactccagc ctggctgtga ggaaatactt ccacagactc 2760
actctctatc tgcaagagaa gaaacacagc ccttgtgcct gggaggttgt cagagcacaa 2820
gtcatgagag ccttctcttc ctcaacaaac ttgcaggaga gtttcaggag aaaggac 2877
<210> 3
<211> 2877
<212> DNA
<213>Genome 2
<400> 3
atgaaatggg ttaccttcat ctctctgctg ctgctgttct cttctgctta ctctcgtggt 60
gttttccgtc gtgacaccca caaatctgaa atcgctcacc gtttcaaaga cctgggtgaa 120
gaacacttca aaggtctggt tctgatcgct ttctctcagt acctgcagca gtgcccgttc 180
gacgaacacg ttaaactggt taacgaactg accgaattcg ctaaaacctg cgttgctgac 240
gaatctcacg ctggttgcga aaaatctctg cacaccctgt tcggtgacga actgtgcaaa 300
gttgcttctc tgcgtgaaac ctacggtgac atggctgact gctgcgaaaa acaggaaccg 360
gaacgtaacg aatgcttcct gtctcacaaa gacgactctc cggacctgcc gaaactgaaa 420
ccggacccga acaccctgtg cgacgaattc aaagctgacg aaaaaaaatt ctggggtaaa 480
tacctgtacg aaatcgctcg tcgtcacccg tacttctacg ctccggaact gctgtactac 540
gctaacaaat acaacggtgt tttccaggaa tgctgccagg ctgaagacaa aggtgcttgc 600
ctgctgccga aaatcgaaac catgcgtgaa aaagttctgg cttcttctgc tcgtcagcgt 660
ctgcgttgcg cttctatcca gaaattcggt gaacgtgctc tgaaagcttg gtctgttgct 720
cgtctgtctc agaaattccc gaaagctgaa ttcgttgaag ttaccaaact ggttaccgac 780
ctgaccaaag ttcacaaaga atgctgccac ggtgacctgc tggaatgcgc tgacgaccgt 840
gctgacctgg ctaaatacat ctgcgacaac caggacacca tctcttctaa actgaaagaa 900
tgctgcgaca aaccgctgct ggaaaaatct cactgcatcg ctgaagttga aaaagacgct 960
atcccggaaa acctgccgcc gctgaccgct gacttcgctg aagacaaaga cgtttgcaaa 1020
aactaccagg aagctaaaga cgcttttctc ggtagcttcc tgtacgaata ctctcgtcgt 1080
cacccggaat acgctgtttc tgttctgctg cgtctggcta aagaatacga agctaccctg 1140
gaagaatgct gcgctaaaga cgacccgcac gcttgctact ctaccgtttt cgacaaactg 1200
aaacacctgg ttgacgaacc gcagaacctg atcaaacaga actgcgacca gttcgaaaaa 1260
ctgggtgaat acggtttcca gaacgctctg atcgttcgtt acacccgtaa agttccgcag 1320
gtttctaccc cgaccctggt tgaagtttct cgttctctgg gtaaagttgg tacccgttgc 1380
tgcaccaaac cggaatctga acgtatgccg tgcaccgaag actacctgtc tctgatcctg 1440
aaccgtctgt gcgttctgca cgaaaaaacc ccggtttctg aaaaagttac caaatgctgc 1500
accgaatctc tggttaaccg tcgtccgtgc ttctctgctc tgaccccgga cgaaacctac 1560
gttccgaaag ctttcgacga aaaactgttc accttccacg ctgacatctg caccctgccg 1620
gacaccgaaa aacagatcaa aaaacagacc gctctggttg aactgctgaa acacaaaccg 1680
aaagctaccg aagaacagct gaaaaccgtt atggaaaact tcgttgcttt cgttgacaaa 1740
tgctgcgctg ctgacgacaa agaagcttgc ttcgctgttg aaggtccgaa actggttgtt 1800
tctacccaga ccgctctggc tggtggtggt ggttctggtg gtggtggttc tatgaaatac 1860
acctcttact tcctggctct gctgctgtgc ggtctgctgg gtttctctgg ttcttacggt 1920
cagggtcagt tcttccgtga aatcgaaaac ctgaaagaat acttcaacgc ttcttctccg 1980
gacgttgcta aaggtggtcc gctgttctct gaaatcctga aaaactggaa agacgaatct 2040
gacaaaaaaa tcatccagtc tcagatcgtt tctttctact tcaaactgtt cgaaaacctg 2100
aaagacaacc aggttatcca gcgttctatg gacatcatca aacaggacat gttccagaaa 2160
ttcctgaacg gttcttctga aaaactggaa gacttcaaaa aactgatcca gatcccggtt 2220
gacgacctgc agatccagcg taaagctatc aacgaactga tcaaagttat gaacgacctg 2280
tctccgaaat ctaacctgcg taaacgtaaa cgttctcaga acctgttccg tggtcgtcgt 2340
gcttctaccg gtggtggtgg ttctggtggt ggtggttctt gccacctgcc gcacacccac 2400
tctctggcta accgtcgtgt tctgatgctg ctgggtcagt tacgtcgtgt aagcccgtct 2460
tcttgcctgc aggaccgtaa cgacttcgct ttcccgcagg aagctctggg tggttctcag 2520
ctgcagaaag ctcaggctat ctctgttctg cacgaagtta cccagcacac cttccagctg 2580
ttctctaccg aaggttctgc taccacctgg gacgaatctc tgctggacaa actgcgtgct 2640
gctctggacc agcagctgac cgacctgcag gcttgcctgc gtcaggaaga agaactgcag 2700
ggtgctccgc tgctgaaaga agactcttct ctggctgttc gtaaatactt ccaccgtctg 2760
accctgtacc tgcaggaaaa aaaacactct ccgtgcgctt gggaagttgt tcgtgctcag 2820
gttatgcgtg ctttctcttc ttctaccaac ctgcaggaat ctttccgtcg taaagac 2877
<210> 4
<211> 1821
<212> DNA
<213>Bovine albumin
<400> 4
atgaagtggg tgacttttat ttctcttctc cttctcttca gctctgctta ttccaggggt 60
gtgtttcgtc gagatacaca caagagtgag attgctcatc ggtttaaaga tttgggagaa 120
gaacatttta aaggcctggt actgattgcc ttttctcagt atctccagca gtgtccattt 180
gatgagcatg taaaattagt gaacgaacta actgagtttg caaaaacatg tgttgctgat 240
gagtcccatg ccggctgtga aaagtcactt cacactctct ttggagatga attgtgtaaa 300
gttgcatccc ttcgtgaaac ctatggtgac atggctgact gctgtgagaa acaagagcct 360
gaaagaaatg aatgcttcct gagccacaaa gatgatagcc cagacctccc taaattgaaa 420
ccagacccca atactttgtg tgatgagttt aaggcagatg aaaagaagtt ttggggaaaa 480
tacctatacg aaattgctag aagacatccc tacttttatg caccagaact cctttactat 540
gctaataaat ataatggagt ttttcaagaa tgctgccaag ctgaagataa aggtgcctgc 600
ctgctaccaa agattgaaac tatgagagaa aaggtactag cttcatctgc cagacagaga 660
ctcaggtgtg ccagtattca aaaatttgga gaaagagctt taaaagcatg gtcagtagct 720
cgcctgagcc agaaatttcc caaggctgag tttgtagaag ttaccaagct agtgacagat 780
ctcacaaaag tccacaagga atgctgccat ggtgacctac ttgaatgcgc agatgacagg 840
gcagatcttg ccaagtacat atgtgataat caagatacaa tctccagtaa actgaaggaa 900
tgctgtgata agcctttgtt ggaaaaatcc cactgcattg ctgaggtaga aaaagatgcc 960
atacctgaaa acctgccccc attaactgct gactttgctg aagataagga tgtttgcaaa 1020
aactatcagg aagcaaaaga tgccttcctg ggctcgtttt tgtatgaata ttcaagaagg 1080
catcctgaat atgctgtctc agtgctattg agacttgcca aggaatatga agccacactg 1140
gaggaatgct gtgccaaaga tgatccacat gcatgctatt ccacagtgtt tgacaaactt 1200
aagcatcttg tggatgagcc tcagaattta atcaaacaaa actgtgacca attcgaaaaa 1260
cttggagagt atggattcca aaatgcgctc atagttcgtt acaccaggaa agtaccccaa 1320
gtgtcaactc caactctcgt ggaggtttca agaagcctag gaaaagtggg tactaggtgt 1380
tgtacaaagc cggaatcaga aagaatgccc tgtactgaag actatctgag cttgatcctg 1440
aaccggttgt gcgtgctgca tgagaagaca ccagtgagtg aaaaagtcac caagtgctgc 1500
acagagtcat tggtgaacag acggccatgt ttctctgctc tgacacctga tgaaacatat 1560
gtacccaaag cctttgatga gaaattgttc accttccatg cagatatatg cacacttccc 1620
gatactgaga aacaaatcaa gaaacaaact gcacttgttg agctgttgaa acacaagccc 1680
aaggcaacag aggaacaact gaaaaccgtc atggagaatt ttgtggcttt tgtagacaag 1740
tgctgtgcag ctgatgacaa agaagcctgc tttgctgtgg agggtccaaa acttgttgtt 1800
tcaactcaaa cagccttagc c 1821
<210> 5
<211> 498
<212> DNA
<213>Ox IFN-γ
<400> 5
atgaaatata caagctattt cttagcttta ctgctctgtg ggcttttggg tttttctggt 60
tcttatggcc agggccaatt ttttagagaa atagaaaact taaaggagta ttttaatgca 120
agtagcccag atgtagctaa gggtgggcct ctcttctcag aaattttgaa gaattggaaa 180
gatgaaagtg acaaaaaaat tattcagagc caaattgtct ccttctactt caaactcttt 240
gaaaacctca aagataacca ggtcattcaa aggagcatgg atatcatcaa gcaagacatg 300
tttcagaagt tcttgaatgg cagctctgag aaactggagg acttcaaaaa gctgattcaa 360
attccggtgg atgatctgca gatccagcgc aaagccataa atgaactcat caaagtgatg 420
aatgacctgt caccaaaatc taacctcaga aagcggaaga gaagtcagaa tctctttcga 480
ggccggagag catcaacg 498
<210> 6
<211> 498
<212> DNA
<213>Ox IFN-α
<400> 6
tgccacctgc ctcacaccca cagcctggcc aacaggaggg tcctgatgct cctgggacaa 60
ctgaggaggg tctccccttc ctcctgcctg caggacagaa atgacttcgc attcccccag 120
gaggcgctgg gtggcagcca gttgcagaag gctcaagcca tctctgtgct ccacgaggtg 180
acccagcaca ccttccagct tttcagcaca gagggctcgg ccactacgtg ggatgagagc 240
ctcctggaca agctccgcgc tgcactggat cagcagctca ctgacctgca agcctgtctg 300
aggcaggagg aggagctgca aggagctccc ctgctcaagg aggactccag cctggctgtg 360
aggaaatact tccacagact cactctctat ctgcaagaga agaaacacag cccttgtgcc 420
tgggaggttg tcagagcaca agtcatgaga gccttctctt cctcaacaaa cttgcaggag 480
agtttcagga gaaaggac 498
<210> 7
<211> 1821
<212> DNA
<213>Bovine albumin
<400> 7
atgaaatggg ttaccttcat ctctctgctg ctgctgttct cttctgctta ctctcgtggt 60
gttttccgtc gtgacaccca caaatctgaa atcgctcacc gtttcaaaga cctgggtgaa 120
gaacacttca aaggtctggt tctgatcgct ttctctcagt acctgcagca gtgcccgttc 180
gacgaacacg ttaaactggt taacgaactg accgaattcg ctaaaacctg cgttgctgac 240
gaatctcacg ctggttgcga aaaatctctg cacaccctgt tcggtgacga actgtgcaaa 300
gttgcttctc tgcgtgaaac ctacggtgac atggctgact gctgcgaaaa acaggaaccg 360
gaacgtaacg aatgcttcct gtctcacaaa gacgactctc cggacctgcc gaaactgaaa 420
ccggacccga acaccctgtg cgacgaattc aaagctgacg aaaaaaaatt ctggggtaaa 480
tacctgtacg aaatcgctcg tcgtcacccg tacttctacg ctccggaact gctgtactac 540
gctaacaaat acaacggtgt tttccaggaa tgctgccagg ctgaagacaa aggtgcttgc 600
ctgctgccga aaatcgaaac catgcgtgaa aaagttctgg cttcttctgc tcgtcagcgt 660
ctgcgttgcg cttctatcca gaaattcggt gaacgtgctc tgaaagcttg gtctgttgct 720
cgtctgtctc agaaattccc gaaagctgaa ttcgttgaag ttaccaaact ggttaccgac 780
ctgaccaaag ttcacaaaga atgctgccac ggtgacctgc tggaatgcgc tgacgaccgt 840
gctgacctgg ctaaatacat ctgcgacaac caggacacca tctcttctaa actgaaagaa 900
tgctgcgaca aaccgctgct ggaaaaatct cactgcatcg ctgaagttga aaaagacgct 960
atcccggaaa acctgccgcc gctgaccgct gacttcgctg aagacaaaga cgtttgcaaa 1020
aactaccagg aagctaaaga cgcttttctc ggtagcttcc tgtacgaata ctctcgtcgt 1080
cacccggaat acgctgtttc tgttctgctg cgtctggcta aagaatacga agctaccctg 1140
gaagaatgct gcgctaaaga cgacccgcac gcttgctact ctaccgtttt cgacaaactg 1200
aaacacctgg ttgacgaacc gcagaacctg atcaaacaga actgcgacca gttcgaaaaa 1260
ctgggtgaat acggtttcca gaacgctctg atcgttcgtt acacccgtaa agttccgcag 1320
gtttctaccc cgaccctggt tgaagtttct cgttctctgg gtaaagttgg tacccgttgc 1380
tgcaccaaac cggaatctga acgtatgccg tgcaccgaag actacctgtc tctgatcctg 1440
aaccgtctgt gcgttctgca cgaaaaaacc ccggtttctg aaaaagttac caaatgctgc 1500
accgaatctc tggttaaccg tcgtccgtgc ttctctgctc tgaccccgga cgaaacctac 1560
gttccgaaag ctttcgacga aaaactgttc accttccacg ctgacatctg caccctgccg 1620
gacaccgaaa aacagatcaa aaaacagacc gctctggttg aactgctgaa acacaaaccg 1680
aaagctaccg aagaacagct gaaaaccgtt atggaaaact tcgttgcttt cgttgacaaa 1740
tgctgcgctg ctgacgacaa agaagcttgc ttcgctgttg aaggtccgaa actggttgtt 1800
tctacccaga ccgctctggc t 1821
<210> 8
<211> 498
<212> DNA
<213>Ox IFN-γ
<400> 8
atgaaataca cctcttactt cctggctctg ctgctgtgcg gtctgctggg tttctctggt 60
tcttacggtc agggtcagtt cttccgtgaa atcgaaaacc tgaaagaata cttcaacgct 120
tcttctccgg acgttgctaa aggtggtccg ctgttctctg aaatcctgaa aaactggaaa 180
gacgaatctg acaaaaaaat catccagtct cagatcgttt ctttctactt caaactgttc 240
gaaaacctga aagacaacca ggttatccag cgttctatgg acatcatcaa acaggacatg 300
ttccagaaat tcctgaacgg ttcttctgaa aaactggaag acttcaaaaa actgatccag 360
atcccggttg acgacctgca gatccagcgt aaagctatca acgaactgat caaagttatg 420
aacgacctgt ctccgaaatc taacctgcgt aaacgtaaac gttctcagaa cctgttccgt 480
ggtcgtcgtg cttctacc 498
<210> 9
<211> 498
<212> DNA
<213>Ox IFN-α
<400> 9
tgccacctgc cgcacaccca ctctctggct aaccgtcgtg ttctgatgct gctgggtcag 60
ttacgtcgtg taagcccgtc ttcttgcctg caggaccgta acgacttcgc tttcccgcag 120
gaagctctgg gtggttctca gctgcagaaa gctcaggcta tctctgttct gcacgaagtt 180
acccagcaca ccttccagct gttctctacc gaaggttctg ctaccacctg ggacgaatct 240
ctgctggaca aactgcgtgc tgctctggac cagcagctga ccgacctgca ggcttgcctg 300
cgtcaggaag aagaactgca gggtgctccg ctgctgaaag aagactcttc tctggctgtt 360
cgtaaatact tccaccgtct gaccctgtac ctgcaggaaa aaaaacactc tccgtgcgct 420
tgggaagttg ttcgtgctca ggttatgcgt gctttctctt cttctaccaa cctgcaggaa 480
tctttccgtc gtaaagac 498
Claims (10)
1. a kind of fusion protein being made of bovine albumin, Bov IFN γ and Bov IFN α, it is characterised in that:The fusion
The amino acid sequence table of albumen is as shown in 400 < of SEQUENCE LISTING, 1 >.
2. a kind of gene of coding fusion protein as described in claim 1, which is characterized in that the nucleotide sequence of the gene
Table is denoted as genome 1 as shown in 400 < of SEQUENCE LISTING, 2 >;Or as shown in 400 < of SEQUENCE LISTING, 3 >,
It is denoted as genome 2.
3. the expression vector containing gene as claimed in claim 2.
4. the genetic engineering bacterium containing gene as claimed in claim 2.
5. a kind of recombinant bovine long-acting interferon, which is characterized in that the recombinant bovine long-acting interferon is melted by described in claim 1
It is freeze-dried to form after hop protein and freeze drying protectant mixture.
6. the preparation method of fusion protein according to claim 1, which is characterized in that the preparation method includes following step
Suddenly:Expression vector described in claim 3 is imported into e. coli host cell, genetic engineering bacterium, genetic engineering are obtained
Bacterium obtains the crude product of the fusion protein after IPTG induced expressions, can be obtained fusion protein after purified.
7. preparation method according to claim 6, which is characterized in that the genetic engineering bacterium is pET-32a/rAlb-IFN
γ-IFN α, preparation method are:
(1) design primer obtains by reverse transcription or is manually respectively synthesized the bovine albumin with flexible linker sequences, Niu Gan
Disturb the target gene of plain γ, Bov IFN α;By flexible linker by bovine albumin, the mesh of Bov IFN γ, Bov IFN α
Gene connect, the nucleotides sequence list of the target gene after connection as shown in 400 < of SEQUENCE LISTING, 2 > or
As shown in 400 < of SEQUENCE LISTING, 3 >;
(2) target gene after connection is connected on pET-32a plasmids and obtains expression vector;
(3) expression vector is imported into e. coli host cell, you can obtain genetic engineering bacterium pET-32a/rAlb-IFN
γ-IFNα。
8. the preparation method described according to claim 6 or 7, which is characterized in that the e. coli host cell is BL21
(DE3) competent cell or BL21 (DE3) competent cell with pGro7 plasmids.
9. the preparation method described according to claim 6 or 7, which is characterized in that the method for the purifying is:Fusion protein it is thick
Product are successively purified through affinity chromatography, anion-exchange chromatography and sieve chromatography.
10. the application of recombinant bovine long-acting interferon according to claim 5, which is characterized in that the recombinant bovine is long-acting dry
The long half time of element is disturbed up to 72 hours or more, there is broad-spectrum disease resistance toxic action and the immune response of Niu Zishen can be improved.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017106757945 | 2017-08-09 | ||
CN201710675794.5A CN107253995A (en) | 2017-08-09 | 2017-08-09 | It is a kind of by bovine albumin, Bov IFN γ and Bov IFN α fusion protein constituted and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108794645A true CN108794645A (en) | 2018-11-13 |
Family
ID=60026700
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710675794.5A Pending CN107253995A (en) | 2017-08-09 | 2017-08-09 | It is a kind of by bovine albumin, Bov IFN γ and Bov IFN α fusion protein constituted and preparation method thereof |
CN201810768833.0A Withdrawn CN108794645A (en) | 2017-08-09 | 2018-07-13 | A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710675794.5A Pending CN107253995A (en) | 2017-08-09 | 2017-08-09 | It is a kind of by bovine albumin, Bov IFN γ and Bov IFN α fusion protein constituted and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107253995A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111087461A (en) * | 2020-01-13 | 2020-05-01 | 武汉科前生物股份有限公司 | Recombinant protein, nucleic acid for coding recombinant protein and application of recombinant protein |
-
2017
- 2017-08-09 CN CN201710675794.5A patent/CN107253995A/en active Pending
-
2018
- 2018-07-13 CN CN201810768833.0A patent/CN108794645A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111087461A (en) * | 2020-01-13 | 2020-05-01 | 武汉科前生物股份有限公司 | Recombinant protein, nucleic acid for coding recombinant protein and application of recombinant protein |
Also Published As
Publication number | Publication date |
---|---|
CN107253995A (en) | 2017-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108840951A (en) | A kind of fusion protein and preparation method thereof being made of pig albumin, Porcine interferon-gamma and porcine interferon alpha | |
CN108840947A (en) | Bovine albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of ox long-acting interferon | |
CN108840952A (en) | A kind of fusion protein and preparation method thereof being made of Chicken Albumin, chicken interferon gamma and chicken interferon α | |
CN108794638A (en) | A kind of recombinant bovine long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon | |
CN108822220A (en) | Sheep albumin-interferon-tau-interleukin-22 fusion protein, preparation method and its encoding gene, a kind of sheep long-acting interferon | |
CN108794645A (en) | A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and Bov IFN α | |
CN108794644A (en) | A kind of fusion protein and preparation method thereof being made of cattle interleukins-2 2, Bov IFN γ and Bov IFN α | |
CN108864295A (en) | A kind of recombinant bovine long-acting interferon and the fusion protein for preparing this long-acting interferon and preparation method thereof | |
CN108822221A (en) | A kind of fusion protein and preparation method thereof being made of Chicken Albumin, chicken interferon gamma and recombinant chIL-2 | |
CN108840935A (en) | A kind of fusion protein being made of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of recombination sheep long-acting interferon γ | |
CN108864300A (en) | Chicken Albumin-interferon-' alpha '-interleukin-22 fusion protein, preparation method and its encoding gene, a breeder long-acting interferon | |
CN108840934A (en) | A kind of recombination sheep long-acting interferon τ and the fusion protein for preparing this long-acting interferon and preparation method thereof | |
CN108864305A (en) | A kind of fusion protein and preparation method thereof being made of sheep albumin, sheep interferon gamma and sheep interferon-tau | |
CN108864301A (en) | A kind of fusion protein and preparation method thereof being made of bovine albumin, Bov IFN γ and cattle interleukins-2 2 | |
CN108864294A (en) | A kind of fusion protein being made of bovine albumin and Bov IFN γ and preparation method thereof and a kind of recombinant bovine long-acting interferon γ | |
CN109053897A (en) | A kind of fusion protein and preparation method thereof being made of recombinant chIL-2, chicken interferon gamma and chicken interferon α | |
CN108840939A (en) | A kind of recombination chicken long-acting interferon α and the fusion protein for preparing this long-acting interferon and preparation method thereof | |
CN108794640A (en) | A kind of Recombinant Swine long-acting interferon γ and the fusion protein and preparation method thereof for preparing this long-acting interferon γ | |
CN107286257A (en) | A kind of Recombinant Swine long-acting interferon α and prepare fusion protein of this long-acting interferon and preparation method thereof | |
CN108840943A (en) | A kind of recombination chicken long-acting interferon γ and the fusion protein and preparation method thereof for preparing this long-acting interferon γ | |
CN108864297A (en) | A kind of recombination chicken long-acting interferon and the fusion protein for preparing this long-acting interferon and preparation method thereof | |
CN107286253A (en) | A kind of fusion protein being made up of OVA and chicken interferon gamma and preparation method thereof and a kind of recombination chicken long-acting interferon γ | |
CN108794643A (en) | A kind of fusion protein and preparation method thereof being made of dog albumin, dog interferon γ and canine leucocyte interleukin 2 | |
CN108840944A (en) | A kind of fusion protein and preparation method thereof being made of sheep albumin, sheep interferon gamma and sheep interleukin 2 | |
CN108864304A (en) | A kind of fusion protein and preparation method thereof being made of dog albumin, dog interferon γ and dog interferon alpha |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181113 |